To evaluate the feasibility and safety of administering surfactant into the nasopharynx during delivery, thus permitting the baby to aspirate the solution into the fluid-filled airway as an air-fluid interface is established. This process avoids the endotracheal intubation (ETI) and positive pressure ventilation (PPV) usually associated with prophylaxis, thus avoiding the pulmonary barotrauma associated with the conventional method of surfactant administration.
INTRODUCTION
Neonatal respiratory distress syndrome (RDS) has historically been the primary illness responsible for the high mortality and morbidity associated with preterm birth. Approximately four decades ago, the cause of RDS was identified as being a deficiency of pulmonary surfactant in the immature lung 1 and during the past decade, prophylaxis and treatment with surfactant has resulted in a substantial decrease in mortality from prematurity. 2 However, many of the survivors of RDS, and even many premature infants who have received surfactant, develop a chronic lung disease, often termed bronchopulmonary dysplasia (BPD), characterized by an arrest in lung development and interference with alveolarization. 3 Recent evidence suggests that endotracheal intubation and positive pressure delivered to the immature, surfactant-deficient lung may exacerbate the development of BPD. 4, 5 Prior to the advent of surfactant prophylaxis and therapy for RDS, it was recognized that application of continuous positive airway pressure (CPAP), either by endotracheal tube (ET) 6 or nasal prongs (nCPAP) 7 could improve alveolar stability and oxygenation in RDS. Recent commentaries have suggested that premature babies who are permitted to breathe spontaneously while given nCPAP immediately following birth may have less surfactant requirements and less development of chronic lung disease than babies who are electively intubated and given PPV. [8] [9] [10] The technique is aimed at avoiding endotracheal intubation and therefore has not permitted surfactant prophylaxis to be given.
We have developed a new technique that employs injection of surfactant into the nasopharynx, followed by mask-and then nasal-CPAP, to deliver surfactant to preterm infants during the birth process. Endotracheal intubation is avoided, except for resuscitation or to deliver prolonged assisted ventilation. This report describes our feasibility study and the outcomes of the babies so treated.
METHODS
The population for this feasibility study included a nonrandom purposive sample of 23 preterm newborns F 18 at the University of Virginia and five at Wesley Medical Center in Wichita F during July 2001 through November 2002. The protocol was approved by the respective Institutional Review Boards and consent was obtained from parents before delivery. The surfactant solution was Infasurf s and was provided without charge by Forest Laboratories. The intent was to include newborns anticipated to deliver at 26 to 30 weeks gestation and with birthweights less than 1500 g. Gestational age was determined by best obstetrical estimate, which usually included a second trimester ultrasound. We excluded those with known congenital malformations, if one of the investigators was unavailable, or if the fetus was demonstrating a nonreassuring fetal heart rate tracing indicating that neonatal resuscitation was considered likely. The latter were excluded because there was usually insufficient time for obtaining informed consent and because the technique required the newborn to be sufficiently healthy to generate adequate spontaneous inspiratory efforts. Characteristics of the infants actually studied are described in Table 1 . In all, 15 infants were delivered vaginally and eight were delivered by Cesarean section.
As soon as the baby's head appeared on the perineum or at the operative incision, the mother was instructed to stop pushing, and the obstetrician suctioned the pharynx and stomach with a size 8-French catheter. The neonatologist then instilled 3.0 ml/kg (based on estimated fetal weight) of a standard surfactant solution into the posterior pharynx through an end-hole catheter. CPAP (10 cmH 2 O) was then administered by mask as the shoulders were delivered and the baby was stimulated to initiate spontaneous respirations. Upon arrival of the baby at the resuscitation table, the CPAP was continued as the baby was dried and transported to the NICU in a transport incubator. nCPAP (6 cmH 2 O) and sufficient F i O 2 to maintain O 2 saturations at 88 to 92% were continued for a minimum of 48 hours. If the baby did not demonstrate sufficient spontaneous respirations, or if resuscitation was otherwise indicated, resuscitation measures were instituted according to guidelines published by the American Academy of Pediatrics and American Heart Association.
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Except for the requirement for nCPAP during the first 48 hours for nonintubated babies, clinical management, including the need for endotracheal intubation and subsequent administration of surfactant, was determined by the attending neonatologist. Data regarding respiratory support, laboratory results, and complications were collected until the babies were discharged to home.
RESULTS
The outcomes are listed in Table 1 . Two of the subjects were small for gestational age (#5 and 6) and two were large for gestational age (#9 and 22). No major complications from the study procedure were encountered during the administration of intrapartum nasopharyngeal surfactant. During vaginal births with vertex presentations, there was always sufficient time (usually approximately 30 to 45 seconds) to suction amniotic fluid from the oropharynx and stomach and for the solution to be injected into the pharynx before the shoulders were delivered and the baby initiated breathing. The only vaginally delivered subject that presented breech (#15) began breathing before the surfactant was injected. Similarly, during Cesarean births it was generally not possible to clear the orophraynx and to inject the surfactant before the baby began breathing.
In all, 13 of the 15 infants delivered vaginally were weaned to r30% oxygen concentrations by 4 hours of age (Table 1) . One (#20) had evidence of hydrops at birth, was intubated at 1 hour of age for worsening respiratory distress, and was subsequently found to have trisomy 21, a pleural effusion, and hydronephrosis. Four other babies were intubated for significant apnea, one of which was felt to be related to maternal narcotics (#19) and one of which developed coincident with the onset of an intraventricular hemorrhage at 44 hours of age. Only one of the 15 babies (#19) developed radiologic signs of RDS and this baby also did not breathe spontaneously at birth, presumably because of maternal narcotics.
There were several complications in the eight babies delivered by Cesarian section, none of which were felt to be related to the protocol. One subject (#5) required resuscitation at birth. The mother had been given general anesthesia and the infant did not initiate breathing following operative delivery. When it became evident that the baby would not initiate respiration, intermittent positive pressure was administered by bag and mask. The remaining surfactant solution was then suctioned from the pharynx and an endotracheal tube was placed without difficulty. Subjects 6 and 7 were discordant twins, delivered for nonreassuring heart rate tracing at 28 weeks, and weighing 560 and 1138 g respectively. In retrospect, these twins met exclusion criteria and should not have been included. The smaller (Twin A) made only weak respiratory efforts in the delivery room and required intubation and conventional surfactant therapy at 6 hours of age. Twin B initially had clear lungs by X-ray, but required endotracheal intubation at 37 hours of age for surgical repair of anal atresia. Subject 8 developed typical RDS, requiring endotracheal intubation and conventional surfactant therapy.
Seven subjects developed symptoms and had ultrasound confirmation of a patent ductus arteriosus. One resolved spontaneously, five resolved following indomethacin therapy, and one required surgical ligation. Five babies developed intracranial bleeding. None required intervention and at the time of discharge all were resolving. None had evidence of periventricular leukomalacia. Six subjects required supplemental oxygen at 36 weeks. Four of the six had been delivered by Cesarian section and had complications as described above. The fifth and sixth had been delivered vaginally, but one had an episode of sepsis at 15 days of age and the other had trisomy 21 and a pleural effusion as described above. All of the subjects survived and were discharged to home after an average length of stay of 56 days. 
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DISCUSSION
Recent evidence suggests that BPD is associated with an elevation of proinflammatory cytokines in the lungs and that such cytokines are induced by the endotracheal intubation and administration of intermittent positive pressure ventilation (PPV) commonly used to initiate and maintain ventilation of the preterm lung. 4 Histologic lung injury and surfactant inactivation have been demonstrated following very brief periods of endotracheal intubation and excessive PPV of the preterm lung. 5 Intubation and PPV are currently required for the standard method of surfactant delivery, either for prophylaxis or treatment of RDS. Although optimum technique of surfactant delivery might strive to minimize delivery of excessive volume, the presence of an endotracheal tube and the need to force the surfactant solution into the lung under positive pressure, increase the likelihood of this complication.
The surfactant administration technique described in this study is designed to administer surfactant to the surfactant-deficient lung by taking advantage of the normal physiologic process of establishing air breathing. Babies born at term normally initiate respirations by first inspiring air and then closing the glottis and attempting to exhale, thus creating a significant positive transpulmonary pressure and presumably forcing fetal lung fluid back into the interstitium of the lung. 12 It is likely that this process results in establishment of an air-fluid interface in the alveolus on which is deposited surfactant that was previously secreted into the fetal lung fluid. However, in the preterm lung, where surfactant is deficient, a similar positive pressure may result in histologic disruption of alveolar integrity, 5 release of cytokines, 13 leakage of serum proteins, 14 and inactivation of any exogenous surfactant that may be administered as prophylaxis or therapy. 15 The technique described in this study is thought to replicate the normal physiologic process described above for the baby born at term, but now in the baby born prematurely. While the chest remains compressed in the birth canal, fetal lung fluid is suctioned from the future upper airway and is replaced with a surfactantcontaining solution. Then, as the chest expands as it is released into the vaginal vault and beyond, the baby is stimulated to aspirate the surfactant-containing solution providing surfactant at the advancing air-fluid interface. This process is facilitated by application of a CPAP delivered by mask.
Enhorning and Robertson 16 were the first to demonstrate that an animal-derived surfactant solution, deposited directly into the tracheas of preterm rabbits via tracheostomies, improved air expansion of the lungs and prolonged survival. These same investigators found that a similar effect could be achieved by depositing the surfactant solution into the posterior pharynges of the rabbits before the first breath, thus permitting the rabbits to aspirate the surfactant with initiation of ventilation. 17 The material was not administered under CPAP, which has been shown to facilitate both endogenous and exogenous surfactant function. 18 A human multicenter trial of artificial surfactant administration versus controls, conducted in the mid-1980s, included a step where surfactant was deposited in the posterior pharynx immediately following birth. 19 However, the material was not administered under CPAP and many of the subjects also received surfactant by endotracheal tube. The outcomes of any subjects treated with pharyngeal surfactant alone were not reported.
The vast majority of human studies of surfactant administration have involved placement of an endotracheal tube after birth, injection of the surfactant solution into the tube, and administration of positive pressure breaths to facilitate distribution of the surfactant throughout the air-filled lung. Investigations of other methods for delivering surfactant to the air-filled lung (e.g., trickle or aerosol delivery) have shown that bolus administration is associated with the most homogeneous distribution in the air-filled lung. 20 Nevertheless, animal studies have shown that surfactant is distributed more uniformly 21 and pulmonary function is maintained for a longer time period 22 if the surfactant is delivered to a fluid-filled versus an air-filled lung. However, it was quickly recognized during the early surfactant studies in humans that the time required for placement of an endotracheal tube made it impossible to administer the surfactant before the first breath. Also, there was fear that delaying the normal establishment of air breathing to accomplish an early intubation might overly stress a premature newborn and would delay the establishment of adequate oxygenation. A controlled trial conducted by Kendig et al. 23 suggested that there was no significant long-term benefit to intubation and surfactant treatment as soon as possible after birth, versus delaying intubation and treatment for a few minutes until the baby had been stabilized. However, both the intervention and control groups in the Kendig trial were given surfactant by endotracheal intubation after air breathing had occurred and both groups received positive pressure for delivery of the surfactant. There is some evidence that the barotrauma associated with the requirement for endotracheal intubation during surfactant prophylaxis may be minimized by early extubation following the surfactant administration. 24 There is only one small controlled study of this technique, although other trials are underway. 25 We believe that the technique described in this report allows the avoidance of barotrauma and establishment of an adequate functional residual capacity, while perhaps still permitting delivery of surfactant to the presumably surfactant-deficient lung. Our experience with babies with vertex presentations and those delivered vaginally suggests that the pharyngeally deposited surfactant may indeed have been aspirated into the lungs. The oxygen requirements were minimal and the chest X-rays showed no evidence of RDS in all but one subject. Although one-third of the vaginally delivered babies were determined by the attending neonatologist to require endotracheal intubation, four were intubated primarily for poor respiratory drive (apnea or high pCO 2 ). Only one infant had radiological evidence of RDS and he also had congenital malformations, including pleural effusions at the time of birth. Two of the 15 developed evidence of chronic lung disease: one was the baby with congenital pleural effusions and the other had no initial signs of respiratory distress, but developed an oxygen requirement associated with sepsis at 15 days of age. Therefore, if the baby with malformations is excluded, none of the vaginally delivered babies developed signs of RDS and only the infant with late onset sepsis developed chronic lung disease. Evidence from previous controlled trials of prophylaxis versus rescue administration of surfactant suggest that approximately 40 to 60% of untreated infants of this gestational age will develop RDS sufficient to qualify for rescue therapy. 26 We are less confident about the potential success of the procedure in babies who are born by breech presentation or by Cesarean section. There are several possible reasons why babies in this feasibility study had a higher incidence of intubation and development of respiratory distress than the babies delivered vaginally. First, several of these babies had congenital malformations or perinatal compromise and the mother of one had received general anesthesia F any of which may have inhibited the vigor of their spontaneous respirations. Perhaps more importantly, it is possible that by having avoided the cervical and vaginal squeeze, these infants may have had excessive residual lung fluid in their tracheobronchial trees and therefore may not have aspirated a sufficient volume of the surfactant solution. Finally, there was some delay in achieving access to the baby's head at the operative incision or to the baby's airway in the baby born vaginally but with breech presentation. This delay resulted in each of the babies taking several spontaneous breaths before receiving surfactant.
In conclusion, nasopharyngeal surfactant instillation during birth appears to be relatively safe and simple to accomplish. We have been unable to devise an experiment to prove that the material reaches the lungs, but believe that the known physiology associated with establishment of air breathing supports such a likelihood, especially for vaginal births with vertex presentations. Proof of efficacy will require a multicenter randomized clinical trial to compare this technique with endotracheal prophylaxis and with nCPAP alone.
